Disease · HP_0005528
Bone marrow hypocellularity
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. Bone marrow hypocellularity. Diseases, record HP_0005528. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/HP_0005528
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Name
- Bone marrow hypocellularity
- Open Targets ID
- HP_0005528
- Other names
- Bone marrow failure, Bone marrow hypoplasia, Hypoplastic bone marrow, Myeloid hypoplasia
- Highest stage of its drugs
- Phase 2/3, for 3 of its 22 drugs, from ClinicalTrials.gov
Source Open Targets
Drugs22
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| FLUDARABINE PHOSPHATE | CHEMBL1096882 | Small molecule | Phase 2/3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| ANTILYMPHOCYTE IMMUNOGLOBULIN (HORSE) | CHEMBL2108981 | Phase 2/3 | ClinicalTrials.gov | 1 | 1 | 0 | Drugs and targets | |
| BUSULFAN | CHEMBL820 | Small molecule | Phase 2/3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| ALEMTUZUMAB | CHEMBL1201587 | Antibody | Phase 2 | ClinicalTrials.gov | 4 | 4 | 4 | Drugs and targets |
| CYCLOSPORINE | CHEMBL160 | Protein | Phase 2 | ClinicalTrials.gov | 3 | 3 | 2 | Drugs and targets |
| FLUDARABINE | CHEMBL1568 | Small molecule | Phase 2 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
| AUTOLOGOUS CORD BLOOD | CHEMBL4594461 | Phase 2 | ClinicalTrials.gov | 2 | 2 | 0 | Drugs and targets | |
| ELTROMBOPAG | CHEMBL461101 | Small molecule | Phase 2 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| RITUXIMAB | CHEMBL1201576 | Antibody | Phase 2 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| TACROLIMUS ANHYDROUS | CHEMBL269732 | Small molecule | Phase 2 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
1 to 10 of 22
See all 22 drugsTargets25
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| CSF3R | Granulocyte colony-stimulating factor receptor | 3 | Granulocyte colony stimulating factor receptor agonist | Phase 1/2 | https://conductscience.org/library/genes/1441 | Drugs and targets |
| FKBP1A | Peptidyl-prolyl cis-trans isomerase FKBP1A | 2 | FK506-binding protein 1A inhibitor | Phase 2 | https://conductscience.org/library/genes/2280 | Drugs and targets |
| RRM1 | Ribonucleoside-diphosphate reductase RR1 | 2 | Ribonucleoside-diphosphate reductase RR1 inhibitor | Phase 2/3 | https://conductscience.org/library/genes/6240 | Drugs and targets |
| RRM2 | Ribonucleoside-diphosphate reductase RR1 | 2 | Ribonucleoside-diphosphate reductase RR1 inhibitor | Phase 2/3 | https://conductscience.org/library/genes/6241 | Drugs and targets |
| RRM2B | Ribonucleoside-diphosphate reductase RR1 | 2 | Ribonucleoside-diphosphate reductase RR1 inhibitor | Phase 2/3 | https://conductscience.org/library/genes/50484 | Drugs and targets |
| AR | Androgen receptor | 1 | Androgen Receptor agonist | Phase 1/2 | https://conductscience.org/library/genes/367 | Drugs and targets |
| CD52 | CAMPATH-1 antigen | 1 | CAMPATH-1 antigen inhibitor | Phase 2 | https://conductscience.org/library/genes/1043 | Drugs and targets |
| IMPDH1 | Inosine-5'-monophosphate dehydrogenase (IMPDH) | 1 | Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor | Phase 2 | https://conductscience.org/library/genes/3614 | Drugs and targets |
| IMPDH2 | Inosine-5'-monophosphate dehydrogenase (IMPDH) | 1 | Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor | Phase 2 | https://conductscience.org/library/genes/3615 | Drugs and targets |
| MPL | Thrombopoietin receptor | 1 | Thrombopoietin receptor agonist | Phase 2 | https://conductscience.org/library/genes/4352 | Drugs and targets |
1 to 10 of 25
See all 25 targetsTrials13
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01328587 | Eltrombopag for Moderate Aplastic Anemia | Phase 2 | 34 | 2019-04-23 | Moderate Aplastic Anemia, Unilineage Bone Marrow Failure Disorders | ELTROMBOPAG | Its record names the disease | ClinicalTrials.gov |
| NCT00058825 | Stem Cell Transplant for Hematologic Diseases | Phase 1/2 | 27 | 2015-10-22 | Hematologic Malignancies | ALEMTUZUMAB, CYCLOSPORINE, FLUDARABINE, TACROLIMUS, TACROLIMUS ANHYDROUS | Its record names the disease | ClinicalTrials.gov |
| NCT00176878 | Stem Cell Transplant for Bone Marrow Failure Syndromes | Phase 2/3 | 10 | 2009-08-06 | Diamond-Blackfan Anemia, Kostmann's Neutropenia, Shwachman-Diamond Syndrome | BUSULFAN, FLUDARABINE PHOSPHATE | Its record names the disease | ClinicalTrials.gov |
| NCT05794425 | Clinical Study of UCB Combined With UC-MSCs in the Treatment of Bone Marrow Failure Disorders | Phase 1/2 | 100 | Bone Marrow Failure Disorders | CYCLOSPORINE | Its record names the disease | ClinicalTrials.gov | |
| NCT03579875 | Alpha/Beta TCD HCT in Patients With Inherited BMF Disorders | Phase 2 | 48 | Fanconi Anemia, Severe Aplastic Anemia, Myelodysplastic Syndromes, T Cell Receptor Alpha/Beta Depletion, Telomere Biology Disorder, Bone Marrow Failure, Dyskeratosis Congenita, Telomere Biology Disorders | ALEMTUZUMAB, RITUXIMAB | Its record names the disease | ClinicalTrials.gov | |
| NCT01659606 | Radiation- and Alkylator-free Bone Marrow Transplantation Regimen for Patients With Dyskeratosis Congenita | Phase 2 | 40 | Dyskeratosis Congenita, Hoyeraal Hreidarsson Syndrome, Revesz Syndrome, Aplastic Anemia | ALEMTUZUMAB, FLUDARABINE, MYCOPHENOLATE MOFETIL, TACROLIMUS ANHYDROUS | Its record names the disease | ClinicalTrials.gov | |
| NCT03710356 | Evaluating Efficacy and Safety of Danazol in Severe Hematologic or Pulmonary Disease Related to Telomeropathy | Phase 1/2 | 40 | Telomere Shortening, Telomere Length, Mean Leukocyte | DANAZOL | Its record names the disease | ClinicalTrials.gov | |
| NCT04965597 | Treosulfan-Based Conditioning Regimen Before a Blood or Bone Marrow Transplant for the Treatment of Bone Marrow Failure Diseases (BMT CTN 1904) | Phase 2 | 40 | Bone Marrow Failure Syndrome, Congenital Amegakaryocytic Thrombocytopenia, Diamond-Blackfan Anemia, Hereditary Sideroblastic Anemia, Paroxysmal Nocturnal Hemoglobinuria, Shwachman-Diamond Syndrome, Hematologic Neoplasm With Germline GATA2 Mutation, Hematologic Neoplasm With Germline SAMD9 Mutation, Hematologic Neoplasm With Germline SAMD9L Mutation | FLUDARABINE PHOSPHATE, TREOSULFAN | Its record names the disease | ClinicalTrials.gov | |
| NCT01720147 | Quercetin in Children With Fanconi Anemia; a Pilot Study | Phase 1 | 30 | Fanconi Anemia | QUERCETIN | Its record names the disease | ClinicalTrials.gov | |
| NCT03206086 | Eltrombopag for Fanconi Anemia | Phase 2 | 25 | Fanconi Anemia | ELTROMBOPAG | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 13
See all 13 trialsComparisons in its trials1
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial |
|---|---|---|---|---|
| Isolex vs CLINIMACs: Number of Patients Who Engrafted With the Isolex/CLINIMACs System | 15 of 19 | 7 of 8 | 27 | NCT00058825 |
Source Trial comparisons
Papers from its trials4
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/HP_0005528
GET https://conductscience.org/api/diseases/v1/HP_0005528/drugs?page=2